OncoMatch/Clinical Trials/NCT06940518
Phase II Trial of Ivonescimab in Previously Treated Patients With Advanced Clear Cell Renal Cell Carcinoma
Is NCT06940518 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Ivonescimab for ivonescimab.
Treatment: Ivonescimab — To learn if ivonescimab can help to control previously treated, locally advanced or metastatic ccRCC.
Check if I qualifyExtracted eligibility criteria
Cancer type
Renal Cell Carcinoma
Disease stage
Required: Stage IV
Metastatic disease required
metastatic/advanced clear cell RCC; at least one measurable site of disease per RECIST version 1.1
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: checkpoint inhibitor — metastatic/advanced
including a PD-1/PD-L1 checkpoint inhibitor administered in metastatic/advanced setting
Lab requirements
Blood counts
adequate organ and marrow function prior to study entry as defined below
Kidney function
adequate organ and marrow function prior to study entry as defined below
Liver function
adequate organ and marrow function prior to study entry as defined below
Cardiac function
Participants with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, participants should be class 2B or better.
Participants must have adequate organ and marrow function prior to study entry as defined below
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- MD Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify